Search

Your search keyword '"Choy, David F."' showing total 50 results

Search Constraints

Start Over You searched for: Author "Choy, David F." Remove constraint Author: "Choy, David F." Topic asthma Remove constraint Topic: asthma
50 results on '"Choy, David F."'

Search Results

1. A targeted amplicon next-generation sequencing assay for tryptase genotyping to support personalized therapy in mast cell-related disorders.

2. Blood transcriptomic signature in type-2 biomarker-low severe asthma and asthma control.

3. A Randomized Trial of a Composite T2-Biomarker Strategy Adjusting Corticosteroid Treatment in Severe Asthma: A Post Hoc Analysis by Sex.

4. Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD.

5. Genome-wide association study identifies kallikrein 5 in type 2 inflammation-low asthma.

6. Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma.

7. Integrated systems modeling of severe asthma: Exploration of IL-33/ST2 antagonism.

8. Exacerbation Profile and Risk Factors in a Type-2-Low Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes.

9. Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation.

10. Steroid-induced fibroblast growth factors drive an epithelial-mesenchymal inflammatory axis in severe asthma.

11. A whole genome sequencing study of moderate to severe asthma identifies a lung function locus associated with asthma risk.

12. Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma.

13. Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires.

14. Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma.

15. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial.

16. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.

17. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).

19. Beyond type 2 cytokines in asthma - new insights from old clinical trials.

20. Nasal gene expression changes with inhaled corticosteroid treatment in asthma.

21. Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma.

22. An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma.

23. A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers.

24. IFN-stimulated Gene Expression, Type 2 Inflammation, and Endoplasmic Reticulum Stress in Asthma.

25. A randomised pragmatic trial of corticosteroid optimization in severe asthma using a composite biomarker algorithm to adjust corticosteroid dose versus standard care: study protocol for a randomised trial.

26. High density lipoproteins and type 2 inflammatory biomarkers are negatively correlated in atopic asthmatics.

27. Seasonal variability of severe asthma exacerbations and clinical benefit from lebrikizumab.

28. A CEACAM6-High Airway Neutrophil Phenotype and CEACAM6-High Epithelial Cells Are Features of Severe Asthma.

29. Peripheral blood gene expression predicts clinical benefit from anti-IL-13 in asthma.

30. Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma.

31. Depletion of major pathogenic cells in asthma by targeting CRTh2.

32. Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK).

33. Biomarkers in the clinical development of asthma therapies.

34. Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response.

35. The airway microbiome in patients with severe asthma: Associations with disease features and severity.

36. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma.

37. IL-13 mediates IL-33-dependent mast cell and type 2 innate lymphoid cell effects on bronchial epithelial cells.

38. A microRNA upregulated in asthma airway T cells promotes TH2 cytokine production.

39. Disconnect between sputum neutrophils and other measures of airway inflammation in asthma.

40. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma.

41. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.

42. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients.

43. Glucocorticoid receptor β and histone deacetylase 1 and 2 expression in the airways of severe asthma.

44. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma.

45. Lung gene expression in a rhesus allergic asthma model correlates with physiologic parameters of disease and exhibits common and distinct pathways with human asthma and a mouse asthma model.

46. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways.

47. T-helper type 2-driven inflammation defines major subphenotypes of asthma.

48. The effects of inhaled corticosteroids on healthy airways.

49. Increased Autophagy-Related 5 Gene Expression Is Associated with Collagen Expression in the Airways of Refractory Asthmatics.

50. Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma.

Catalog

Books, media, physical & digital resources